Gene Therapy Proven to Shield Brain from TDP-43 Damage

An experimental gene therapy called SynCav1 can protect the central nervous system from the cognitive decline linked to TDP-43-related proteinopathy, a primary driver of FTD, ALS, and over half of all Alzheimers cases.